Granted Patent B2

US 12,466,823 · App. 17/610,939 · Granted Nov 11, 2025

Inventors: Yidong Su (Shanghai, CN); Jun Wang (Shanghai, CN); Rudi Bao (Shanghai, CN)

Assignees: SHANGHAI HANSOH BIOMEDICAL CO., LTD.; JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.

C07D471/04A61P35/00C07D471/08C07D519/00

Abstract

Claims (109)

1 . A compound represented by general formula (IX-B), or a pharmaceutically acceptable salt thereof:

wherein:

M 3 is selected from bond, —O—, —S—, —NH— or —NCH 3 —;

R 18 and R 19 are each independently selected from hydrogen, deuterium, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, halogen, amino, nitro, hydroxyl, cyano, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, 3-12 membered heterocyclyl, C 6-10 aryl or 5-12 membered heteroaryl;

or, R 18 and R 19 together with the carbon atoms they are attached to form a C 3-8 cycloalkyl or a 3-12 membered heterocyclyl;

R 20 is selected from cyano, or C 2-6 alkynyl;

or,

is selected from

R 24 and R 25 are each independently selected from hydrogen, deuterium, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, halogen, amino, nitro, hydroxyl, cyano, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, 3-12 membered heterocyclyl, C 6-10 aryl, 5-12 membered heteroaryl or —(CH 2 ) n1 OR aa ;

or, R 24 and R 25 together with the carbon atoms they are attached to and G2 form a C 3-8 cycloalkyl or 3-12 membered heterocyclyl;

r is 0, 1 or 2;

L is selected from bond, —(CH 2 ) n1 CR aa R bb —, —(CH 2 ) n1 NR aa C(O)(CH 2 ) n2 —, —(CH 2 ) n1 C(O)(CH 2 ) n2 (CR aa R bb ) m —, —(CH 2 ) n1 C(O)(CR aa R bb ) m (CH 2 ) n2 —, —(CH 2 ) n1 C(O)NR cc (CR aa R bb ) n2 —, —(CH 2 ) n1 (O)(CH 2 ) n2 — or —(CH 2 ) n1 NR aa (CH 2 ) n2 —;

G 2 is selected from N or CR aa ;

M 1 is selected from N or CR aa ;

M 2 is selected from N or CR aa ;

R 9 is selected from hydrogen, deuterium, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, halogen, amino, nitro, hydroxyl, cyano, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, 3-12 membered heterocyclyl, C 6-10 aryl, 5-12 membered heteroaryl or —(CH 2 ) n1 OR aa ;

R aa , R bb and R cc are each independently selected from hydrogen, deuterium, cyano, amino, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, hydroxyl, C 3-8 cycloalkyl, 3-12 membered heterocyclyl or C 6-14 aryl, wherein the C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, hydroxyl, C 3-8 cycloalkyl, 3-12 membered heterocylcyl and C 6-14 aryl are optionally further substituted by one or more substituents selected from hydrogen, halogen, cyano, hydroxyl, oxo, imino, C 1-6 alkyl or C 1-6 hydroxyalkyl;

or, any two of R aa , R bb and R cc are optionally connected to form a C 3-8 cycloalkyl or a 3-12 membered heterocyclyl, wherein the C 3-8 cycloalkyl and 3-12 membered heterocyclyl are optionally further substituted by one or more substituents selected from hydrogen, amino, halogen, cyano, hydroxyl, oxo, imino, C 1-6 alkyl or C 1-6 hydroxyalkyl;

n1 is 0, 1 or 2;

n2 is 0, 1 or 2;

m is 0, 1 or 2; and

s is 0, 1, 2 or 3.

2 . A compound represented by general formula (IX-C), or a pharmaceutically acceptable salt thereof:

wherein:

R 21 and R 22 together with the atoms they are attached to form a azetidinyl or 2-azaspiro[3.3]heptane, wherein the azetidinyl or 2-azaspiro[3.3]heptane are optionally further substituted by one or more substituents selected from hydrogen, amino, halogen, cyano, hydroxyl, oxo, C 1-6 alkyl or C 1-6 hydroxyalkyl;

R 24 and R 25 are each independently selected from hydrogen, deuterium, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, halogen, amino, nitro, hydroxyl, cyano, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, 3-12 membered heterocyclyl, C 6-10 aryl, 5-12 membered heteroaryl or —(CH 2 ) n1 OR aa ;

or, R 24 and R 25 together with the carbon atoms they are attached to and G2 form a C 3-8 cycloalkyl or 3-12 membered heterocyclyl;

L is selected from bond, —(CH 2 ) n1 CR aa R bb —, —(CH 2 ) n1 NR aa C(O)(CH 2 ) n2 —, —(CH 2 ) n1 C(O)(CH 2 ) n2 (CR aa R bb ) m —, —(CH 2 ) n1 C(O)(CR aa R bb ) m (CH 2 ) n2 —, —(CH 2 ) n1 C(O)NR cc (CR aa R bb ) n2 —, —(CH 2 ) n2 (O)(CH 2 ) n2 — or —(CH 2 ) n1 NR aa (CH 2 ) n2 —;

G 2 is selected from N or CR aa ;

M 1 is selected from N or CR aa ;

M 2 is selected from N or CR aa ;

R 9 is selected from hydrogen, deuterium, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, halogen, amino, nitro, hydroxyl, cyano, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, 3-12 membered heterocyclyl, C 6-10 aryl, 5-12 membered heteroaryl or —(CH 2 ) n1 OR aa ;

R aa , R bb and R cc are each independently selected from hydrogen, deuterium, cyano, amino, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, hydroxyl, C 3-8 cycloalkyl, 3-12 membered heterocyclyl or C 6-14 aryl, wherein the C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, hydroxyl, C 3-8 cycloalkyl, 3-12 membered heterocylcyl and C 6-14 aryl are optionally further substituted by one or more substituents selected from hydrogen, halogen, cyano, hydroxyl, oxo, imino, C 1-6 alkyl or C 1-6 hydroxyalkyl;

or, any two of R aa , R bb and R cc are optionally connected to form a C 3-8 cycloalkyl or a 3-12 membered heterocyclyl, wherein the C 3-8 cycloalkyl and 3-12 membered heterocyclyl are optionally further substituted by one or more substituents selected from hydrogen, amino, halogen, cyano, hydroxyl, oxo, imino, C 1-6 alkyl or C 1-6 hydroxyalkyl;

n1 is 0, 1 or 2;

n2 is 0, 1 or 2;

m is 0, 1 or 2; and

s is 0, 1, 2 or 3.

3 . A compound, or a pharmaceutically acceptable salt thereof, wherein, the specific structure of the compound is as follows:

4 . The compound as defined in claim 3 , or the pharmaceutically acceptable salt thereof, wherein, the specific structure of the compound is as follows:

5 . A compound represented by general formula (XI) or (XI-A), or a pharmaceutically acceptable salt thereof:

wherein:

R 12 is selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxyl, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl;

R 13 is selected from alkenyl, alkynyl, —(C≡C) n1 (CR aa R bb ) m R cc , —(C═C) n1 (CR aa R bb ) m R cc , —(CH 2 ) n1 O(CH 2 ) n2 (CR aa R bb ) m R cc , wherein the alkenyl or alkynyl are optionally further substituted by one or more substituents selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted cyanoalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, substituted or unsubstituted amino, nitro, hydroxyl, cyano, oxo, thio, imino, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —(CH 2 ) n1 R dd , —(CH 2 ) n1 OR dd , —(CH 2 ) n1 S(CH 2 ) n2 R dd , —(CH 2 ) n1 C(O)R dd , —(CH 2 ) n1 C(O)OR dd , —(CH 2 ) n1 S(O)R dd , —(CH 2 ) n1 S(O)(═NR dd )(CH 2 ) n2 R ee , —(CH 2 ) n1 NR dd R ee , —(CH 2 ) n1 P(O)R dd R ee , —(CH 2 ) n1 C(O)NR dd R ee , —(CH 2 ) n1 NR dd C(O)R ee or —(CH 2 ) n1 NR dd S(O) m R ee ;

R 14 is selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxyl, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl;

R 15 and R 16 are each independently selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxyl, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or —(CH 2 ) n1 OR aa ;

L is selected from bond, —(CH 2 ) n1 CR aa R bb —, —(CH 2 ) n1 NR aa C(O)(CH 2 ) n2 —, —(CH 2 ) n1 C(O)(CH 2 ) n2 (CR aa R bb ) m —, —(CH 2 ) n1 C(O)(CR aa R bb ) m (CH 2 ) n2 —, —(CH 2 ) n1 C(O)NR cc (CR aa R bb ) n2 —, —(CH 2 ) n1 (O)(CH 2 ) n2 — or —(CH 2 ) n1 NR aa (CH 2 ) n2 —;

R 11 is selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxyl, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —(CH 2 ) n1 R aa , —(CH 2 ) n1 OR aa , —(CH 2 ) n1 S(CH 2 ) n2 R aa , —(CH 2 ) n1 C(O)R aa , —(CH 2 ) n1 C(O)OR aa , —(CH 2 ) n1 S(O) m R aa , —(CH 2 ) n1 S(O)(═NR aa )(CH 2 ) n2 R bb , —(CH 2 ) n1 NR aa R bb , —(CH 2 ) n1 P(O)R aa R bb , —(CH 2 ) n1 C(O)NR aa R bb , —(CH 2 ) n1 NR aa C(O)R bb or —(CH 2 ) n1 NR aa S(O) m R bb ;

R aa , R bb , R dd and R ee are each independently selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, cyano, nitro, hydroxyl, amino, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally further substituted by one or more substituents selected from hydrogen, deuterium, unsubstituted alkyl, unsubstituted deuterated alkyl, unsubstituted haloalkyl, unsubstituted alkoxy, unsubstituted haloalkoxy, halogen, cyano, nitro, hydroxyl, amino, oxo, imino, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted heterocyclyl, unsubstituted aryl, or unsubstituted heteroaryl;

R cc is selected from cyano or alkynyl; or

any two of R aa , R bb , R dd and R ee are connected to form a cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally further substituted by one or more substituents selected from hydrogen, deuterium, unsubstituted alkyl, unsubstituted deuterated alkyl, unsubstituted haloalkyl, unsubstituted alkoxy, unsubstituted haloalkoxy, halogen, cyano, nitro, hydroxyl, amino, oxo, imine, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted heterocyclyl, unsubstituted aryl, or unsubstituted heteroaryl;

m is 0, 1 or 2;

n1 is 0, 1, 2 or 3; and

n2 is 0, 1, 2 or 3.

6 . The compound as defined in claim 1 , or the pharmaceutically acceptable salt thereof, wherein, R 18 and R 19 in the general formula (IX-B) are each independently selected from hydrogen, methyl, ethynyl, amino, cyano or hydroxyl;

or, R 18 and R 19 together with the carbon atoms they are attached to form a C 3-6 cycloalkyl or 3-7 membered heterocyclyl comprising 1-2 oxygen atoms, nitrogen atoms or sulfur atoms;

R 20 is ethynyl, or cyano;

R 24 and R 25 are each independently selected from hydrogen or methyl;

or, R 24 and R 25 together with the carbon atoms they are attached to and G2 form a azetidinyl,

L is selected from —CH 2 —, —CD 2 -, —O—, —S—, —C(O)NH— or —NHC(O)—;

G 2 is selected from —N—, —CH— or —CCH 3 —;

M 1 is selected from —N—, —CH— or —CCH 3 —;

M 2 is selected from —N— or —CH—;

R 9 is selected from hydrogen, fluorine, chlorine, methyl, methoxy, deuterated methoxy or cyclopropoxy.

7 . The compound as defined in claim 5 , or the pharmaceutically acceptable salt thereof, wherein, the general formula (XI) is further represented by general formula (XIII):

wherein:

R 11 is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl or C 2-6 alkynyl;

R 13 is selected from C 2-6 alkenyl, C 2-6 alkynyl, or —O(CH 2 ) n1 (CR aa R bb ) m R cc ;

R aa and R bb are each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl or C 2-6 alkynyl;

R cc is selected from cyano or C 2-6 alkynyl;

M 1 is —CH—;

M 2 is —N—:

R 16 is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl or C 2-6 alkynyl;

R a is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl or C 2-6 alkynyl;

R b is hydrogen;

n1 is an integer of 1, 2 or 3;

m is an integer of 1, 2 or 3.

8 . The compound as defined in claim 7 , or the pharmaceutically acceptable salt thereof, wherein,

R 11 is cyano;

R 13 is selected from C 2-4 alkenyl, C 2-4 alkynyl, —OCH 2 CR aa R bb R cc ;

R aa and R bb are each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy, C 1-3 haloalkoxy, C 2-4 alkenyl or C 2-4 alkynyl;

R cc is cyano or C 2-6 alkynyl;

M 1 is —CH—;

M 2 is —N—;

R 16 is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy or C 1-3 haloalkoxy;

R a is selected from hydrogen, deuterium or halogen;

R b is hydrogen.

9 . The compound as defined in claim 1 , or the pharmaceutically acceptable salt thereof, wherein,

is selected from

10 . The compound as defined in claim 2 , or the pharmaceutically acceptable salt thereof, wherein,

R 24 and R 25 are each independently selected from hydrogen or methyl;

or, R 24 and R 25 together with the carbon atoms they are attached to and G2 form a azetidiny.

11 . A pharmaceutical composition comprising a therapeutically effective amount of the compound as defined in claim 1 , or the pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

12 . A pharmaceutical composition comprising a therapeutically effective amount of the compound as defined in claim 2 , or the pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

13 . A pharmaceutical composition comprising a therapeutically effective amount of the compound as defined in claim 5 , or the pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

14 . A method for preparing the compound represented by general formula (IX-B) as defined in claim 1 , or the pharmaceutically acceptable salt thereof, wherein, comprising the following steps:

a reaction is carried out with general formula (IX-B1) and general formula (IX-B2) to obtain the compound represented by general formula (IX-B) or the pharmaceutically acceptable salt thereof;

wherein:

R 28 is selected from halogen, boric acid or borate ester; preferably fluorine, chlorine, bromine, iodine, —B(OH) 2 or

R 29 is selected from halogen, boric acid or borate ester; preferably fluorine, chlorine, bromine, iodine, —B(OH) 2 or

when R 28 is halogen, R 29 is selected from boric acid or borate ester;

when R 28 is selected from boric acid or borate ester, R 29 is halogen.

15 . A method for preparing the compound represented by general formula (IX-C) as defined in claim 2 , the stereoisomer thereof or the pharmaceutically acceptable salt thereof, wherein, comprising the following steps:

a reaction is carried out with general formula (IX-C1) and general formula (IX-C2) to obtain the compound represented by general formula (IX-C) or the pharmaceutically acceptable salt thereof;

wherein:

X 2 is selected from halogen.

16 . A method for the treatment of non-small cell lung cancer, medullary thyroid carcinoma, and thyroid papillary tumor, comprising administering to a patient a therapeutically effective dose of the compound as defined in claim 1 , or the pharmaceutically acceptable salt thereof.

17 . A method for the treatment of non-small cell lung cancer, medullary thyroid carcinoma, and thyroid papillary tumor, comprising administering to a patient a therapeutically effective dose of the compound as defined in claim 2 , or the pharmaceutically acceptable salt thereof.

18 . A method for the treatment of non-small cell lung cancer, medullary thyroid carcinoma, and thyroid papillary tumor, comprising administering to a patient a therapeutically effective dose of the compound as defined in claim 5 , the stereoisomer thereof or the pharmaceutically acceptable salt thereof.

Assignments (1)

Priority Claims (5)

Continuity (1)

References Cited (48)